MX2023002482A - Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. - Google Patents

Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.

Info

Publication number
MX2023002482A
MX2023002482A MX2023002482A MX2023002482A MX2023002482A MX 2023002482 A MX2023002482 A MX 2023002482A MX 2023002482 A MX2023002482 A MX 2023002482A MX 2023002482 A MX2023002482 A MX 2023002482A MX 2023002482 A MX2023002482 A MX 2023002482A
Authority
MX
Mexico
Prior art keywords
dialysis
antagonist
prevention
treatment
active ingredient
Prior art date
Application number
MX2023002482A
Other languages
English (en)
Inventor
Ryosuke Mihara
Tomohisa Saito
Keiko Hirokawa
Naoki Fukazawa
Fumie Okada
Tetsuya Hirahara
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2023002482A publication Critical patent/MX2023002482A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a una composición farmacéutica para la prevención y/o tratamiento de prurito urémico que comprende un antagonista de IL-31 como un ingrediente activo.
MX2023002482A 2020-09-01 2020-09-01 Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. MX2023002482A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2020/032987 WO2022049614A1 (ja) 2020-09-01 2020-09-01 Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物

Publications (1)

Publication Number Publication Date
MX2023002482A true MX2023002482A (es) 2023-03-08

Family

ID=73741045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002482A MX2023002482A (es) 2020-09-01 2020-09-01 Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.

Country Status (10)

Country Link
US (1) US20230391878A1 (es)
EP (1) EP4209227A1 (es)
JP (2) JP6799831B1 (es)
KR (2) KR20230048233A (es)
CN (1) CN116096411A (es)
AU (1) AU2020466800A1 (es)
CA (1) CA3189847A1 (es)
IL (1) IL300694A (es)
MX (1) MX2023002482A (es)
WO (1) WO2022049614A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
JP2002338476A (ja) * 2001-05-21 2002-11-27 Health Factor Kenkyusho:Kk 腎透析に伴う痒みの予防治療剤
EP2338910B1 (en) 2002-01-18 2015-07-08 ZymoGenetics, Inc. Cytokine receptor Zcytor17 multimers
ZA200606461B (en) 2004-02-12 2008-02-27 Lexicon Pharmaceuticals Inc Gene disruptions, compositions and methods relating thereto
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
US20060188499A1 (en) 2005-02-14 2006-08-24 Leung Donald Y Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
US20060182743A1 (en) 2005-02-14 2006-08-17 Janine Bilsborough Methods of treating skin disorders using an IL-31RA antagonist
CN101198624B (zh) 2005-05-06 2012-10-10 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
EP1991581A2 (en) * 2006-01-10 2008-11-19 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
RU2009111884A (ru) 2006-09-01 2010-10-10 Займоджинетикс, Инк. (Us) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
MX2010006097A (es) 2007-12-05 2010-08-04 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para tratar el prurito.
RU2531521C2 (ru) 2007-12-05 2014-10-20 Чугаи Сейяку Кабусики Кайся Антитело против nr10 и его применение
EP2796466B1 (en) 2007-12-07 2017-11-22 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
WO2014208645A1 (ja) * 2013-06-28 2014-12-31 中外製薬株式会社 そう痒を伴う疾患に罹患した患者のｉｌ－３１アンタゴニストによる治療に対する応答を予測する方法
WO2015025767A1 (ja) * 2013-08-21 2015-02-26 久光製薬株式会社 貼付剤
US20190135804A1 (en) * 2017-11-03 2019-05-09 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Compositions and methods for the inhibition of pruritus
KR102156932B1 (ko) * 2017-11-23 2020-09-17 주식회사 헬릭스미스 천연추출물을 포함하는 소양증의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
KR102269716B1 (ko) 2021-06-28
EP4209227A1 (en) 2023-07-12
CA3189847A1 (en) 2022-03-10
JP6799831B1 (ja) 2020-12-16
JPWO2022049614A1 (es) 2022-03-10
KR20230048233A (ko) 2023-04-11
WO2022049614A1 (ja) 2022-03-10
CN116096411A (zh) 2023-05-09
IL300694A (en) 2023-04-01
AU2020466800A1 (en) 2023-03-23
JP2022041802A (ja) 2022-03-11
US20230391878A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
MX2022002465A (es) Inhibidores de kras g12d.
SG11201907038WA (en) Quinazoline compound
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
WO2020086747A3 (en) Ssao inhibitors and uses thereof
NZ738524A (en) Pharmaceutical formulations comprising rilpivirine hydrochloride, tenofovir alafenamide hemifumarate, and emtricitabine
MX2023002482A (es) Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
MX2020012989A (es) Agente terapeutico para la fibrosis.
PH12017500436A1 (en) Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2023004188A (es) Compuestos fosfolipidos y usos de estos.
MX2021006102A (es) Suministro mejorado de agentes grandes.
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
MX2022006312A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
CR20220600A (es) Inhibidores de glucosilceramidasa no lisosomal y los usos de los mismos
MX2020006886A (es) Sistema para suministro de medicamento.
PH12019502662A1 (en) Compounds
MX2019001210A (es) Composicion farmaceutica anticancer.
MX2021000732A (es) Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo para tratar ham.
MX2020013385A (es) Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion.
MX2022003129A (es) Uso de un inhibidor de mdm2 para el tratamiento de la mielofibrosis.
MX2023003087A (es) Compuesto de pirimido pirimidinona y composicion farmaceutica que comprenden el mismo.